The DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.
C-Raf Is Required for the Initiation of Lung Cancer by K-RasG12D
Open accessPublished version of a preprint
Abstract
Abstract The Ras/Raf/MEK/ERK (extracellular signal–regulated kinase) pathway is primarily responsible for mitogenesis in metazoans, and mutational activation of this pathway is common in cancer. A variety of selective chemical inhibitors directed against the mitogen-activated protein kinase pathway are now available for clinical investigation and thus the determination of the importance of each of the kinases in oncogenesis is paramount. We investigated the role of two Raf kinases, B-Raf and C-Raf, in Ras oncogenesis, and found that although B-Raf and C-Raf have overlapping functions in primary mesenchymal cells, C-Raf but not B-Raf is required for the proliferative effects of K-RasG12D in primary epithelial cells. Furthermore, in a lung cancer mouse model, C-Raf is essential for tumor initiation by oncogenic K-RasG12D, whereas B-Raf is dispensable for this process. Our findings reveal that K-RasG12D elicits its oncogenic effects primarily through C-Raf and suggest that selective C-Raf inhibition could be explored as a therapeutic strategy for K-Ras–dependent cancers. Significance: Ras is one of the most prevalent oncogenes in human cancer; however, it is considered “undruggable.” Therefore, increasing our understanding of the importance of Ras effectors, including the Raf/MEK/ERK pathway, will create novel avenues for therapeutic intervention. Cancer Discovery; 1(2); 128–36. © 2011 AACR. Read the Commentary on this article by Rebocho and Marais, p. 98 This article is highlighted in the In This Issue feature, p. 91
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Together, these studies provided compelling evidence that C-Raf, but not B-Raf or A-Raf, may mediate the oncogenic signaling in KRAS-driven cancer.”
From New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness (2019) · cites this paper as [75]
In the citing paper
“Recent studies showed that C-RAF rather than B-RAF plays a crucial role in mediating KRAS oncogenic signaling (74, 75).”
From New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness (2019) · cites this paper as [75]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-rasPreprint
Jackson, E. L., Willis, N. A., Mercer, K. L., Bronson, R. T., Crowley, D. G., Montoya, R., Jacks, T., & Tuveson, D. A. (2001) · Genes & Development · doi:10.1101/gad.943001 · Cited by 1,927
Self-citationRAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
Poulikakos, P. I., Zhang, C., Bollag, G. E., Shokat, K. M., & Rosen, N. X. (2010) · Nature · doi:10.1038/nature08902 · Cited by 1,841
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
Hatzivassiliou, G., Song, K. W., Yen, I., Brandhuber, B. J., Anderson, D. J., Alvarado, R., Ludlam, M. J. C., Stokoe, D., Gloor, S. L., Vigers, G. P. A., et al. (2010) · Nature · doi:10.1038/nature08833 · Cited by 1,649
Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
Heidorn, S. J., Milagre, C. S., Whittaker, S. R., Nourry, A., Niculescu‐Duvaz, I., Dhomen, N. S., Hussain, J., Reis-Filho, J. S., Springer, C. J., Pritchard, C. A., et al. (2010) · Cell · doi:10.1016/j.cell.2009.12.040 · Cited by 1,497
Engelman, J. A., Chen, L., Tan, X., Crosby, K., Guimaraes, A. R., Upadhyay, R., Maira, M., McNamara, K., Perera, S. A., Song, Y., et al. (2008) · Nature Medicine · doi:10.1038/nm.1890 · Cited by 1,330
Tuveson, D. A., Shaw, A. T., Willis, N. A., Silver, D. P., Jackson, E. L., Chang, S., Mercer, K. L., Grochow, R., Hock, H., Crowley, D., et al. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00085-6 · Cited by 798
Self-citationRegulation of Raf-1 by direct feedback phosphorylation.
Dougherty, M., Müller, J., Ritt, D. A., Zhou, M., Zhou, X.-Z., Copeland, T., Conrads, T., Veenstra, T., Lu, K., & Morrison, D. (2005) · Molecules and Cells · doi:10.1016/j.molcel.2004.11.055 · Cited by 663
Binding of Ras to Phosphoinositide 3-Kinase p110α Is Required for Ras- Driven Tumorigenesis in Mice
Gupta, S., Ramjaun, A. R., Haiko, P., Wang, Y., Warne, P. H., Nicke, B., Nye, E. L., Stamp, G., Alitalo, K. K., & Downward, J. (2007) · Cell · doi:10.1016/j.cell.2007.03.051 · Cited by 603
Species- and cell type-specific requirements for cellular transformation
Rangarajan, A., Hong, S. J., Gifford, A., & Weinberg, R. A. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.07.009 · Cited by 576
Cited by
Sorted by citations
Items 101–150 of 150
KRASG12C inhibitor: combing for combination
Chakraborty, A. (2020) · Biochemical Society Transactions · doi:10.1042/bst20200473 · Cited by 15
New RAF kinase inhibitors in cancer therapy
Martín-Liberal, J., & Larkin, J. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.911286 · Cited by 14
Modeling K-Ras-driven lung adenocarcinoma in mice: preclinical validation of therapeutic targets
Drosten, M., & Barbacid, M. (2015) · Journal of Molecular Medicine · doi:10.1007/s00109-015-1360-5 · Cited by 12
Sakai, T. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108234 · Cited by 12
Grading of lung adenocarcinomas with simultaneous segmentation by artificial intelligence (GLASS-AI)
Lockhart, J. H., Ackerman, H. D., Lee, K., Abdalah, M. A., Davis, A. J., Hackel, N., Boyle, T. A., Saller, J. J., Keske, A., Hänggi, K., et al. (2023) · npj Precision Oncology · doi:10.1038/s41698-023-00419-3 · Cited by 12
Non‐canonical Raf‐1/p70S6K signalling in non–small‐cell lung cancer
Qiu, Z., Ye, B., Zhao, S., Li, X., Li, L., Mo, X.-M., & Li, W. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14636 · Cited by 12
Phase I/II RAF kinase inhibitors in cancer therapy
Turajlic, S., Ali, Z., Yousaf, N., & Larkin, J. (2013) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.797964 · Cited by 11
Inhibitors of the ERK Mitogen-Activated Protein Kinase Cascade for Targeting RAS Mutant Cancers
Gentry, L. R., Samatar, A. A., & Der, C. J. (2013) · The Enzymes · doi:10.1016/b978-0-12-420146-0.00004-4 · Cited by 14
New Insight Puts CRAF in Sight as a Therapeutic Target
Rebocho, A. P., & Marais, R. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0118 · Cited by 11
Three distinct regions of cRaf kinase domain interact with membrane
Prakash, P., Hancock, J. F., & Gorfe, A. A. (2019) · Scientific Reports · doi:10.1038/s41598-019-38770-w · Cited by 11
Recent Anti-KRASG12D Therapies: A “Possible Impossibility” for Pancreatic Ductal Adenocarcinoma
Sobhani, N., Pittacolo, M., D’Angelo, A., & Marchegiani, G. (2025) · Cancers · doi:10.3390/cancers17040704 · Cited by 12
Sankarasubramanian, S., Pfohl, U., Regenbrecht, C. R. A., Reinhard, C., & Wedeken, L. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.760705 · Cited by 7
Enzyme meets a surprise target
Deuker, M. M., & McMahon, M. (2014) · Nature · doi:10.1038/nature13343 · Cited by 7
RAF1 kinase contributes to autophagic lysosome reformation
Toifl, S., Didusch, S., Ehrenreiter, K., Desideri, E., Dorard, C., & Baccarini, M. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115490 · Cited by 7
Self-citationSIRT4 as a novel interactor and candidate suppressor of C-RAF kinase in MAPK signaling
Mehrabipour, M., Nakhaei‐Rad, S., Dvorský, R., Lang, A., Verhülsdonk, P., Ahmadian, M. R., & Piekorz, R. P. (2024) · Life Science Alliance · doi:10.26508/lsa.202302507 · Cited by 5
Hayes, T. K., & Der, C. J. (2014) · Springer eBooks · doi:10.1007/978-3-7091-1806-1_6 · Cited by 6
Han, D., Zhou, Y., Zhang, K., Gai, C., Zhang, P., Chai, X., Zhuo, X., Zhao, Q., Zou, Y., & Zhu, L. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117568 · Cited by 4
Wang, J., Sarkar, A., García, N., Zhang, L., Calizo, A., Lisok, A., Campos, K., He, F., Punjaala, N., Marple, T. C., et al. (2025) · Molecular Medicine · doi:10.1186/s10020-025-01353-9 · Cited by 4
Li, M., Zhang, G., Tang, Q., Xi, K., Lin, Y., & Chen, W. (2024) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2024.108292 · Cited by 4
The RAS Signaling Network and Cancer
Hibshman, P. S., & Der, C. J. (2024) · Springer eBooks · doi:10.1007/978-3-031-62945-7_17 · Cited by 4
Ihle, N. T. (2012) · Digital Commons-TMC (Texas Medical Center) · Cited by 4
Ovejero, L. D. L. P., Fernández-Rodríguez, A., Francoz, S., Aizpurua, G., Lomba-Riego, L., Drosten, M., Guerra, C., Musteanu, M., Barbacid, M., & García‐Alonso, S. (2026) · PLoS ONE · doi:10.1371/journal.pone.0341778 · Cited by 1
Jiang, H., Muir, R. K., Gonciarz, R. L., Olshen, A. B., Yeh, I., Hann, B. C., Zhao, N., Wang, Y.-H., Behr, S. C., Evans, M. J., et al. (2020) · SSRN Electronic Journal · doi:10.2139/ssrn.3581366 · Cited by 2
Illuminating DEPDC1B in Multi-pronged Regulation of Tumor Progression
Boudreau, H. E., Robinson, J., & Kasid, U. N. (2023) · Methods in molecular biology · doi:10.1007/978-1-0716-3163-8_21 · Cited by 1
Exploiting c-RAF dependency in RAS mutant cancer: beyond catalytic activity
Cooke, S. F., & Blair, C. M. (2024) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2024.2319035 · Cited by 2
Zhang, X., Wong, W., Cho, H. S., Yang, D., Dixon, G., Luo, R., Liu, D., Torre, D., Umeda, S., Gonzãlez, F., et al. (2026) · Developmental Cell · doi:10.1016/j.devcel.2026.04.012 · Cited by 2
Progress in Targeting RAF Kinases for Cancer Therapy
Turbyville, T. J., & Holderfield, M. T. (2015) · Personalized Medicine · doi:10.2217/pme.15.1 · Cited by 1
Partners in Crime: Clandestine Operations among RAS-RAF Accomplices in Promoting Tumorigenesis
Venkatanarayan, A., & Malek, S. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.11.020 · Cited by 1
Next-Generation Strategies to Target RAF
Stuart, D. D. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803505-4.00010-2
KRAS: The Art of Understanding a Complex Gene
Velasco, W. V., Ramos-Castaneda, M. A., Clowers, M. J., Deng, S., & Moghaddam, S. J. (2020) · Elsevier eBooks · doi:10.1016/b978-0-08-102723-3.00003-2
KRAS G12D can be targeted by potent salt-bridge forming inhibitorsPreprint
Mao, Z., Xiao, H., Shen, P., Yang, Y., Xue, J. W., Yang, Y., Shang, Y., Zhang, L., Li, X., Zhang, Y., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.13.472365
Characterization of The Growth Factor Receptor Network Oncogenes in Lung Cancer
Duche, A. (2021) · Chapman University Digital Commons (Chapman University) · doi:10.36837/chapman.000306
Sakai, T. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4047655
O’Bryan, J. P. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.733983450.793559493
The Design, Synthesis, and Evaluation of Evodiamine Derivatives with Hydroxy Groups
Yang, Z., Guo, H., Zhang, K., Jiang, Z., Jin, R., Guo, D., Li, Z., Wang, Y., & Meng, L. (2022) · Letters in Drug Design & Discovery · doi:10.2174/1570180819666220903150621
Data from Targeting Glucose Metabolism Sensitizes Pancreatic Cancer to MEK Inhibition
Yan, L., Tu, B., Yao, J., Gong, J., Carugo, A., Bristow, C. A., Wang, Q., Zhu, C., Dai, B., Kang, Y., et al. (2023) · doi:10.1158/0008-5472.c.6512998.v1
Yan, L., Tu, B., Yao, J., Gong, J., Carugo, A., Bristow, C. A., Wang, Q., Zhu, C., Dai, B., Kang, Y., et al. (2023) · doi:10.1158/0008-5472.22428364.v1
García, N., Pozo, V. D., Yohe, M. E., Goodwin, C. M., Shackleford, T. J., Wang, L., Baxi, K., Chen, Y., Rogojina, A. T., Zimmerman, S. M., et al. (2023) · doi:10.1158/1535-7163.c.6543340.v1
Target Hyperactive ERK Signaling for Cancer Therapy
Yap, J., & Hu, J. (2023) · Springer eBooks · doi:10.1007/978-3-030-80962-1_257-1
Mehrabipour, M., Dvorský, R., Nakhaei‐Rad, S., Lang, A., Verhülsdonk, P., Ahmadian, M. R., & Piekorz, R. P. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.11.23.568463
Spencer-Smith, R. (2024) · Journal of Visualized Experiments · doi:10.3791/66436
A BAG-1-inhibitory peptide, GO-Pep, suppresses c-Raf activity in cancer
Tatlı, Ö., Cebi, E., Türk, M., Dingiloğlu, B., Sezan, A., Basturk, E., Temur, B. Z., Eyüpoğlu, A. E., Bicak, B., Erdal, E., et al. (2025) · Communications Biology · doi:10.1038/s42003-024-07419-4
Target Hyperactive ERK Signaling for Cancer Therapy
Yap, J., & Hu, J. (2025) · Springer eBooks · doi:10.1007/978-3-032-00771-1_257
Zhang, X., Wong, W. D., Cho, H., Yang, D., Dixon, G., Luo, R., Liu, D., Torre, D., Umeda, S., Gonzãlez, F., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.03.09.710586
Ghousein, A. (2018) · theses.fr (ABES) · doi:10.70675/ec7734c8zd6cdz40d5z9291ze7613c3b0d23
Rôle de la kinase ARAF dans le mélanome cutané muté NRAS
Estrada, C. (2020) · theses.fr (ABES) · doi:10.70675/e84b4f6az1676z4c2dz80e4zd8668460d3c5
Mitochondrial Raf1 regulates glutamine catabolism
Shanderson, R. L., Ferguson, I., Ducoli, L., Miao, W., Srinivasan, S., Siprashvili, Z., Li, A. M., Velasco, M. G. M., Li, Y., Hoang, C. N., et al. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.117975
BindingDB (2019) · UC San Diego · doi:10.7270/q2f191zc
BindingDB (2016) · UC San Diego · doi:10.7270/q2zs2z85
Lentiviral-Based Approach for the Validation of Cancer Therapeutic Targets in Vivo
Ambrogio, C., Stern, P., Scuoppo, C., Kranz, H. D., Barbacid, M., & Santamarı́a, D. (2014) · BioTechniques · doi:10.2144/000114214
Metadata
- Authors
- Karreth, F. A., Frese, K. K., DeNicola, G. M., Baccarini, M., & Tuveson, D. A.
- Affiliations
- University of Vienna (AT)
- Venue
- Cancer Discovery
- Published
- 2011-07-01
- Volume
- 1
- Issue
- 2
- Pages
- 128-136
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC3203527
- OpenAlex
- W2133177414
- Cited by
- 149
- References
- 29
- Citations by year
- 2026: 4 · 2025: 7 · 2024: 9 · 2023: 12 · 2022: 9 · 2021: 13 · 2020: 8 · 2019: 8 · 2018: 12 · 2017: 11 · 2016: 10 · 2015: 13 · 2014: 14 · 2013: 9 · 2012: 8
- FWCI
- 4.28
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Cancer Research UK (A10211)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- Raf-1, BRAF, lung cancer, RAS/MAPK pathway, carcinogenesis, tumor initiation, Raf kinase inhibition, Ras effectors, epithelial cell proliferation
- MeSH terms
- Animals, Cell Transformation, Neoplastic, Epithelial Cells, Fibroblasts, Lung, Lung Neoplasms, Mutation, Transformation, Genetic, ras Proteins, Proto-Oncogene Proteins c-raf, Mitogen-Activated Protein Kinases, MAP Kinase Signaling System, Extracellular Signal-Regulated MAP Kinases, Proto-Oncogene Proteins B-raf, Cell Growth Processes, Mice, Mice, 129 Strain, Mesenchymal Stem Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
